Jonathan G Drachman Selected Research

dacetuzumab

1/2015	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
6/2014	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.
2/2013	Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.
5/2010	A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma.
2/2010	A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.
9/2009	Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jonathan G Drachman Research Topics

Disease

6	Neoplasms (Cancer) 06/2014 - 06/2005
4	Thrombocytopenia (Thrombopenia) 08/2009 - 01/2004
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2015 - 02/2013
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2013 - 09/2009
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2009 - 06/2005
1	Infections 01/2015
1	Cytopenia 01/2015
1	Cough 01/2015
1	Lymphoma (Lymphomas) 06/2014
1	Multiple Myeloma 05/2010
1	Inflammation (Inflammations) 05/2010
1	Cytokine Release Syndrome 05/2010
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2010
1	Conjunctivitis 09/2009
1	Chills 08/2009
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2006
1	Polyploidy 07/2005
1	Hemorrhage 07/2005
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2004
1	Purpura 01/2004
1	Thrombocytopenia 1 02/2003
1	Wiskott-Aldrich Syndrome 02/2003

Drug/Important Bio-Agent (IBA)

6	dacetuzumabIBA 01/2015 - 09/2009
4	Monoclonal AntibodiesIBA 06/2014 - 09/2009
2	Rituximab (Mabthera)FDA Link 01/2015 - 02/2013
2	Immunoconjugates (Immunoconjugate)IBA 01/2013 - 10/2006
1	Ifosfamide FDA LinkGeneric 01/2015
1	Carboplatin (JM8)FDA LinkGeneric 01/2015
1	Vincristine (Oncovin)FDA LinkGeneric 01/2015
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2015
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2015
1	Prednisolone (Predate)FDA LinkGeneric 01/2015
1	Etoposide (VP 16)FDA LinkGeneric 01/2015
1	Immunoglobulin G (IgG)IBA 06/2014
1	Gemcitabine FDA Link 02/2013
1	AntibodiesIBA 01/2013
1	EnzymesIBA 05/2010
1	SteroidsIBA 05/2010
1	Serine (L-Serine)FDA Link 08/2009
1	lintuzumabIBA 08/2009
1	Messenger RNA (mRNA)IBA 08/2009
1	Threonine (L-Threonine)FDA Link 08/2009
1	Phosphotransferases (Kinase)IBA 08/2009
1	Docetaxel (Taxotere)FDA Link 10/2006
1	SU 6656IBA 07/2005
1	Thrombopoietin (c-mpl Ligand)IBA 07/2005
1	Transcription Factors (Transcription Factor)IBA 06/2005
1	Inosine Triphosphate (ITP)IBA 01/2004
1	Proteins (Proteins, Gene)FDA Link 02/2003

Therapy/Procedure

4	Therapeutics 01/2013 - 07/2005
1	Salvage Therapy 01/2015
1	Immunotherapy 06/2014
1	Drug Therapy (Chemotherapy) 10/2006
1	Splenectomy 08/2004